期刊文献+

不同血液净化模式对维持性血液透析患者蛋白结合类毒素的清除效果 被引量:35

Removal efficacy of protein-bound uraemic toxins by different blood purification strategies
下载PDF
导出
摘要 目的:探讨不同血液净化方式对维持性血液透析(MHD)患者蛋白结合类毒素清除的效果。方法:选取符合入选标准的MHD患者136例,经4周洗脱期,随机分成4组:低通量血液透析(LFHD)组、高通量血液透析(HFHD)组,血液透析滤过(HDF)组和血液透析联合血液灌流(HD+HP)组,采用高效液相色谱串联质谱法(HPLC-MS/MS)方法测定不同血液净化方法治疗前后血清、透析废液和血液灌流器中马尿酸(HA)、硫酸对甲酚(PCS)、硫酸吲哚酚(IS)、3-羧基-4-甲基-5-丙基-2-呋喃丙酸(CMPF)的浓度,观察对蛋白结合类毒素的清除效果。结果:四种模式皆能有效清除HA,各组之间无差异。对血清PCS的清除,HDF组和HD+HP组的下降率高于LFHD组(P<0.01)和HFHD组(P<0.05,P<0.01)。对血清IS的清除,HDF组和HD+HP组高于LFHD组、HFHD组(均P<0.05)。对于血清CMPF的清除,HD+HP组和HDF组明显高于LFHD组、HFHD组(P<0.01),HD+HP组高于HDF组(P<0.01),LFHD组与HFHD组相比无差别(P>0.05)。结论:四种方式对于蛋白结合力较低的蛋白结合类毒素清除效率接近于小分子毒素的清除效果;HDF、HD+HP对中等蛋白结合力的蛋白结合类毒素的清除能力优于HFHD、LFHD;HD+HP清除高蛋白结合力的蛋白结合毒素的能力最佳,HDF次之,LFHD和HFHD几乎无效。 Objective:To compare the efficiency of protein-bound uraemic toxins removal by four main strategies [ low-flux hemodialysis ( LFHD ), high-flux hemodialysis ( HFHD ), hemodiafihration (HDF) and hemoperfusion ( HD + HP).] Methodology: This study was a prospective, randomized clinical trial. 136 maintenance hemodialysi (MHD) patients were selected and after four weeks of run-in period they were randomly divided into four groups : LFHD group, HFHD group,HDF group and HD+HP group.Removal of hippuric acid(HA) ,p-cresyl sulfate (PCS) ,indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid(CMPF) was determined by reduction ratios (RRs) and total solute removal (TSR) in continuously collected dialysate and HD + HP apparatus by high-performance liquid chromatography tandem mass spect-rometry ( HPLC-MS/MS ). Results: Plasma levels of the protein-bound toxins were significantly decreased by all treatment forms,but the removal effective were different.As for HA,the reduction rate were no difference in each group (P〉0.05).As for PCS,HDF and HD+HP have higher RR than LFHD (P〈0.01) and HFHD (P〈0.05,P〈 0.01) .As for IS,HDF and HD+HP have higher RR than LFHD (P〈O. 05) and HFHD (P〈0. 05). CMPF can hardly remove in LFHD and HFHD ,while HDF and HD+HP have higher RR than LFHD (P〈0. O1 ) and HFHD (P〈O. 01 ). And HD+HP was higher than HDF (P〈0. 01 ). Conclusion:The remove efficacy of low affinity to human serum albumin protein-bound toxin were not significant different among groups. To remove middle affinity to human serum albumin protein- bound toxins, HDF and HD + HP were superior to HFHD and LFHD. To remove high affinity to human serum albumin protein-bound toxins, HDF and HD+HP can be partially removed, and HD+HP is the best. While HFHD and LFHD were hardly to remove.
出处 《肾脏病与透析肾移植杂志》 CAS CSCD 北大核心 2016年第5期425-430,共6页 Chinese Journal of Nephrology,Dialysis & Transplantation
关键词 蛋白结合类毒素 低通量血液透析 高通量血液透析 血液透析滤过 血液灌流 protein-bound uremic toxin low-flux hemodialysis high-flux hemodialysis hemodiafiltration hemoperfusion combined with hemodialysis
  • 相关文献

参考文献4

二级参考文献52

  • 1[1]Sato T, Shoji H, Koga N. Endotoxin adsorption by polymyxin B immo bileized fiber column in patients with systemic inflammatory rssponse syndrome: The Japanese Experiense, Therapeutic Apheresis and Dialysis,2003,7(2) :252 - 258
  • 2[2]Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis:Endotoxin adsorption cartridge(Toraymyxin). Therapeutic Apheresis and Dialysis, 2003,7(1):108 - 114
  • 3[3]Schmaldienst S, Banyai S, Stulnig TM, et al. Prospective randomised cross- over comparison of three LDL - apheresis system in stain pretreated patients with familial hypercholesterolaemia. Athernsclerosis,2000,151(2) :493 - 7
  • 4[4]Ritter M. M, Parhofer K.G. Extracorporal low - density lipoprotein by innunoadsorption. Therapeutic Apheresis and Dialysis, 2003, 7 ( 3 ):370 - 372
  • 5[5]Nakaji S, Haynshi N. Adsorption for myasthenia gravis treatment:Medisorba MG - 50. Therapeutic Apheresis and dialysis, 2003,7 ( 1 ):78 - 84
  • 6[6]Hirata N, Kuriyama T, Yamawaki N. Immusorba TR and PH. Therapeutic Apheresis and Dialysis, 2003,7( 1 ) :85 - 90
  • 7[7]Bambauer R,Schiel R, Latza R,et al. LDL apheresis in clinical practice: long - term treatment of severe hyperlipidemia. Ther Apher, 1997,1(1): 49-51
  • 8[8]Brunton C, Varghese Z, Moorhead F. Lipoheresis in the nephrotic syndrome. kidney Int,1999,56(Suppl 71) :s6- s8
  • 9[9]Yamamoto T,Yammashita T. Low - density lioprotein apheresis using the liposorber system: feature and clinical benefits. Ther Apher, 1998, 2(1) :25- 30
  • 10[10]Bosch T, Keller C. Clinical effect of direct adorption of lipoprotein apheresis: Beyond cholesterol reduction. Therapeutic Apheresis and Dialysis, 2003, 7(3) :341 - 344

共引文献113

同被引文献280

引证文献35

二级引证文献223

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部